miR-155 stimulates bCSC chemoresistance to doxorubicin by targeting CD44, CD90, and ABCG2, and inhibiting miR-155 resensitizes MDA-MB-231 BC cells to doxorubicin (212). This evidence concerns the gene CD44 and breast cancer.